Texas Biotech (TXB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: E. Graphs who wrote (163)	4/30/1997 4:51:00 AM
From: X. Fang	of 834

If you compare chart of TXB with the Biotech Index IXBTX, you will be breathing a little easier. On the weekly chart, TXB is still holding above its long term trend line. RSI does not look that bad either. The problem is whether investors still have faith in this company or not. The most recent Lehman report on TXB was on the 17th of April. They reaffirmed their strong buy rating and $16 target. "We continue to offer that there is significant inherent value in Texas Biotechnology that is not being recognized by Wall Street. We propose that the following news events will reinforce our thesis: * Novastan pivotal results (HIT) in mid to late May * Novastan data presentations (HIT) at thrombosis conference in June * Novastan Phase II data (acute mi) from partner Synthelabo this summer * Novastan corporate partner to be signed this summer * Novastan NDA filing (HIT) by year-end * TBC 11251 Phase II program (CHF) to begin 2Q/3Q * TBC 1269 Phase II program (asthma) to begin 2Q/3Q" "..... As these events unfold, we suggest that current investors will be rewarded as the share price begins to reflect the value created." Good luck to us all.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next